Skip to Main Content

Paper Details

Outcomes by <i>EGFR</i>, <i>KRAS</i>, and <i>ALK</i> Genotype After Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
JCO Precis Oncol
7
2018
Author NameAffiliation
Hugo J W L AertsDana-Farber Cancer Institute Raymond H. Mak, Brigham and Women's Hospital Raymond H. Mak, Harvard Medical School and Paul Catalano, Harvard School of Public Health Boston
David KozonoDana-Farber Cancer Institute Raymond H. Mak, Brigham and Women's Hospital Raymond H. Mak, Harvard Medical School and Paul Catalano, Harvard School of Public Health Boston
Pasi A J??nneDana-Farber Cancer Institute Raymond H. Mak, Brigham and Women's Hospital Raymond H. Mak, Harvard Medical School and Paul Catalano, Harvard School of Public Health Boston
  • 1 - 3

Datasets